On Nov. 9, King Pharmaceuticals
- Sales declined by 5.1% to $491.7 million because King's best-selling products, Altace and Skelaxin, were down compared with last year.
- Net income decreased by 25.8% to $90.4 million, because of lower revenues and higher operating expenses.
- King Pharmaceuticals is a five-star stock in Motley Fool CAPS.
(Figures in millions, except per-share data)
Income Statement Highlights
|
Q3 2006 |
Q3 2005 |
Change |
|
|---|---|---|---|
|
Sales |
$491.7 |
$518.0 |
(5.1%) |
|
Net Profit* |
$89.9 |
$122.6 |
(26.7%) |
|
EPS |
$0.37 |
$0.50 |
(26.0%) |
|
Diluted Shares |
242.8 |
241.9 |
0.4% |
Get back to basics with a look at the income statement.
Margin Checkup
|
Q3 2006 |
Q3 2005 |
Change* |
|
|---|---|---|---|
|
Gross Margin |
78.4% |
82.2% |
(3.8) |
|
Operating Margin |
25.1% |
36.2% |
(11.1) |
|
Net Margin |
18.3% |
23.7% |
(5.4) |
Margins are the earnings engine. See how they work.
Balance Sheet Highlights
|
Assets |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Cash + ST Invest. |
$917.1 |
$651.2 |
40.8% |
|
Accounts Rec. |
$255.7 |
$252.0 |
1.5% |
|
Inventory |
$186.8 |
$218.7 |
(14.6%) |
|
Liabilities |
Q3 2006 |
Q3 2005 |
Change |
|---|---|---|---|
|
Accounts Payable |
$80.8 |
$58.1 |
39.1% |
|
Long-Term Debt |
$404.3 |
$345.0 |
17.2% |
Learn the ways of the balance sheet.
Cash Flow Highlights
A statement of cash flows wasn't provided in the earnings release.
Find out why Fools always follow the money.
Related Companies:
-
KOS
Pharmaceuticals
(NASDAQ:KOSP) -
ENDO Pharmaceuticals
(NASDAQ:ENDP) -
Abraxis BioScience
(NASDAQ:ABBI) -
Teva Pharmaceutical
(NASDAQ:TEVA)
Related Foolishness:
For a fun new way to do research on stocks, check out CAPS, the Fool's new investment community.
Fool by Numbers is designed to give you the raw earnings information in a timely fashion, putting all the numbers you need in one easy-to-read place. But at The Motley Fool, we believe numbers tell only part of the story, so check Fool.com for more of our in-depth discussion of what the numbers mean. This data has been provided by Netscribes. To provide feedback on this article, please click on the "feedback" button below.
